MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition

Molecular and Cellular Biology

Volumn 33, Issue 11, 2013, Pages 2260-2274

  Zawistowski, Jon S ^a   Nakamura, Kazuhiro ^a   Parker, Joel S ^a   Granger, Deborah A ^a   Golitz, Brian T ^a   Johnson, Gary L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CLAUDIN; MICRORNA 9; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; SELUMETINIB; SMALL INTERFERING RNA; TRAMETINIB;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GENETIC SCREENING; GENETIC VARIABILITY; PRIORITY JOURNAL; PROMOTER REGION; RNA METHYLATION; TUMOR SUPPRESSOR GENE;

3' UNTRANSLATED REGIONS; ANTIGENS, CD29; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CLAUDINS; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MAP KINASE KINASE KINASES; MICRORNAS; PYRIDONES; PYRIMIDINONES;

EID: 84878980752     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00269-13     Document Type: Article

References (60)

1. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. 2011. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71.
2. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. 2010. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-972.
3. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M. 2010. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/ PI3K. Cancer Cell 18:683-695.
4. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG. 2009. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11:448-458, 2 p following 458.
5. Perou CM. 2010. Molecular stratification of triple-negative breast cancers. Oncologist 15(Suppl. 5):39-48.
6. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. 2010. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12:R68. doi:10.1186/bcr2635.
7. Baldwin A, Grueneberg DA, Hellner K, Sawyer J, Grace M, Li W, Harlow E, Munger K. 2010. Kinase requirements in human cells. V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc. Natl. Acad. Sci. U. S. A. 107:12463-12468.
8. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong K-K, Elledge SJ. 2009. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848.
9. Tsai K-W, Liao Y-L, Wu C-W, Hu L-Y, Li S-C, Chan W-C, Ho M-R, Lai C-H, Kao H-W, Fang W-L, Huang K-H, Lin W. 2011. Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics 6:1189-1197.
10. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan P-F, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, Gomez SM, Chen X, Jin J, Frye SV, Earp HS, Graves LM, Johnson GL. 2012. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149:307-321.
11. Li Q, Chow AB, Mattingly RR. 2010. Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogenactivated protein kinase kinase inhibitors. J. Pharmacol. Exp. Ther. 332: 821-828.
12. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E. 2007. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogenactivated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13:1576-1583.
13. Griffiths-Jones S, Saini HK, Van Dongen S, Enright AJ. 2008. miRBase: tools for microRNA genomics. Nucleic Acids Res. 36:D154-D158.
14. Betel D, Wilson M, Gabow A, Marks DS, Sander C. 2008. The microRNA.org resource: targets and expression. Nucleic Acids Res. 36:D149-D153.
15. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, Mac-Menamin P, Da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. 2005. Combinatorial microRNA target predictions. Nat. Genet. 37:495-500.
16. Friedman RC, Farh KK-H, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92-105.
17. Alam N, Goel HL, Zarif MJ, Butterfield JE, Perkins HM, Sansoucy BG, Sawyer TK, Languino LR. 2007. The integrin-growth factor receptor duet. J. Cell. Physiol. 213:649-653.
18. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA. 2010. miR-9, a MYC/ MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12:247-256.
19. Onnis A, De Falco G, Antonicelli G, Onorati M, Bellan C, Sherman O, Sayed S, Leoncini L. 2010. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One 5:e12960. doi:10.1371/journal.pone .0012960.
20. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. 2000. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14:2501-2514.
21. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, Zappacosta F, Annan R, Sutton D, Laquerre SG. 2011. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17:989-1000.
22. Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, Länger F, Kreipe H. 2008. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J. Pathol. 214:17-24.
23. Hsu P-Y, Deatherage DE, Rodriguez BAT, Liyanarachchi S, Weng Y-I, Zuo T, Liu J, Cheng ASL, Huang TH-M. 2009. Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res. 69:5936-5945.
24. Minor J, Wang X, Zhang F, Song J, Jimeno A, Wang X-J, Lu X, Gross N, Kulesz-Martin M, Wang D, Lu S-L. 2012. Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. Oral Oncol. 48:73-78.
25. Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, Altenberger C, Minichsdorfer C, Lang G, Döme B, End-Pfützenreuter A, Arns B-M, Grin Y, Klepetko W, Zielinski CC, Zöchbauer-Müller S. 2012. Genomewide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin. Cancer Res. 18:1619-1629.
26. Kitano K, Watanabe K, Emoto N, Kage H, Hamano E, Nagase T, Sano A, Murakawa T, Nakajima J, Goto A, Fukayama M, Yatomi Y, Ohishi N, Takai D. 2011. CpG island methylation of microRNAs is associated with tumor size and recurrence of non-small-cell lung cancer. Cancer Sci. 102:2126-2131.
27. Xiong Z, Laird PW. 1997. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25:2532-2534.
28. Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70.
29. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH. 1989. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J. Cell Biol. 109:877-889.
30. Wong KY, Yu L, Chim CS. 2011. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics 3:83-92.
31. Yuva-Aydemir Y, Simkin A, Gascon E, Gao F-B. 2011. MicroRNA-9: functional evolution of a conserved small regulatory RNA. RNA Biol. 8:557-564.
32. Shibata M, Nakao H, Kiyonari H, Abe T, Aizawa S. 2011. MicroRNA-9 regulates neurogenesis in mouse telencephalon by targeting multiple transcription factors. J. Neurosci. 31:3407-3422.
33. Bonev B, Pisco A, Papalopulu N. 2011. MicroRNA-9 reveals regional diversity of neural progenitors along the anterior-posterior axis. Dev. Cell 20:19-32.
34. Leucht C, Stigloher C, Wizenmann A, Klafke R, Folchert A, Bally-Cuif L. 2008. MicroRNA-9 directs late organizer activity of the midbrainhindbrain boundary. Nat. Neurosci. 11:641-648.
35. Laneve P, Gioia U, Andriotto A, Moretti F, Bozzoni I, Caffarelli E. 2010. A minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiation. Nucleic Acids Res. 38:6895-6905.
36. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. 2008. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 28:14341-14346.
37. Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, Li Y, Lee-Messer C, Dolmetsch RE, Tsien RW, Crabtree GR. 2011. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476:228-231.
38. Kasinski AL, Slack FJ. 2011. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11:849-864.
39. Leucci E, Zriwil A, Gregersen LH, Jensen KT, Obad S, Bellan C, Leoncini L, Kauppinen S, Lund AH. 2012. Inhibition of miR-9 derepresses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene 31:5081-5089.
40. Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E. 2011. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro. Oncol. 13:1090-1098.
41. Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R. 2012. Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol. Rep. 27: 1759-1764.
42. Zhou H, Huang X, Cui H, Luo X, Tang Y, Chen S, Wu L, Shen N. 2010. miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 116: 5885-5894.
43. Li G, Zhang L, Chen E, Wang J, Jiang X, Chen JH, Wickman G, Amundson K, Bergqvist S, Zobel J, Buckman D, Baxi SM, Bender SL, Casperson GF, Hu-Lowe DD. 2010. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity. Cancer Res. 70:10243-10254.
44. Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, Weiss G, Yazji S, Ng C, Wilding G. 2008. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res. 14:7924-7929.
45. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, Rabbani SA. 2006. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 5:2271-2280.
46. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A. 2000. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res. 60: 309-320.
47. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM. 2003. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 104:496-503.
48. Stragies R, Osterkamp F, Zischinsky G, Vossmeyer D, Kalkhof H, Reimer U, Zahn G. 2007. Design and synthesis of a new class of selective integrin alpha5beta1 antagonists. J. Med. Chem. 50:3786-3794.
49. Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Löffler KU, Adamis AP, Knolle J. 2009. Preclinical evaluation of the novel smallmolecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch. Ophthalmol. 127:1329-1335.
50. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang Y-C, Shou J, Bissell MJ, Osborne CK, Schiff R. 2011. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 13:R84. doi:10.1186/bcr2936.
51. Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, Saylor VL, McMahon M. 2001. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEKextracellular signal-regulated kinase signaling pathway. Mol. Cell. Biol. 21:3192-3205.
52. Aguirre Ghiso JA, Kovalski K, Ossowski L. 1999. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147:89-104.
53. Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu Davis IAS, Webster JD, Hoover S, Simpson RM, Gauldie J, Green JE. 2010. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 70:5706-5716.
54. Tabariès S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, Russo C, Hassanain M, Metrakos P, Diaz Z, Basik M, Bertos N, Park M, Guettier C, Adam R, Hallett M, Siegel PM. 2011. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 30:1318-1328.
55. Hollestelle A, Elstrodt F, Nagel JHA, Kallemeijn WW, Schutte M. 2007. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 5:195-201.
56. Liu ML, Von Lintig FC, Liyanage M, Shibata MA, Jorcyk CL, Ried T, Boss GR, Green JE. 1998. Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene 17:2403-2411.
57. Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. 2012. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin. Cancer Res. 18:5290-5303.
58. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB. 2012. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367:2316-2321.
59. Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE. 2007. Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep. 8:70-76.
60. Gravgaard KH, Lyng MB, Laenkholm A-V, Søkilde R, Nielsen BS, Litman T, Ditzel HJ. 2012. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res. Treat. 134:207-217.